ZURICH, Oct 15 (Reuters) - Roche on Thursday confirmed its full-year 2020 outlook for low- to mid-single-digit percentage sales growth as revenue from COVID-19 tests and newer drugs help balance out declining sales from older medicines that are no longer on patent.
Revenue through September slipped 5% to 44 billion Swiss francs ($48.21 billion), Roche said in a statement, down from 46 billion francs in the year-earlier period as the rising value of the Swiss franc eroded reported revenue.
Sales rose 1% in constant currencies.
$1 = 0.9127 Swiss francs Reporting by John Miller; Editing by Michael Shields
Our Standards: The Thomson Reuters Trust Principles.